Skip to main content
Terug
RAPP logo

Rapport Therapeutics, Inc. Common Stock

Datakwaliteit: 100%
RAPP
NASDAQ Healthcare Biotechnology
€ 28,25
▲ € 0,34 (1,22%)
Marktkapitalisatie: 1,03B
Dagbereik
€ 26,98 € 28,30
52-Weeksbereik
€ 7,73 € 42,27
Volume
189.345
50D / 200D Gem.
€ 28,03 / € 23,20
Vorige Slotkoers
€ 27,91

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -9,3 0,3
P/B 2,1 2,9
ROE % -28,2 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 43,33 +53.4%
Low: € 40,00 High: € 47,00
Forward WPA
-€ 3,36
Omzet Sch.
13 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 -€ 3,58
-€ 3,58 – -€ 3,58
66 M 1
FY2029 -€ 4,74
-€ 4,74 – -€ 4,74
30 M 1
FY2028 -€ 4,77
-€ 5,47 – -€ 3,28
0 5

Belangrijkste Punten

Debt/Equity of 0,02 — conservative balance sheet
Negative free cash flow of -88,09M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-28,22%
ROIC-18,91%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,02
Current Ratio26,17
Interest Coverage0,00

Waardering

P/E Ratio
-9,25
P/B Ratio2,13
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -111,48M
ROE -28,22% ROA -21,76%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -88,09M
ROIC -18,91% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,02 Current Ratio 26,17
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -9,25 P/B Ratio 2,13
P/S Ratio N/A PEG Ratio -0,02
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,03B Enterprise Value 989,90M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 0,0 0,0 0,0 0,0
Net Income -111,48M -78,31M -34,79M -10,65M
EPS (Diluted) -2,86 -0,38 -0,19 -0,05
Gross Profit -1,02M -839.000,0 -112.000,0 -15.000,0
Operating Income -125,10M -83,06M -36,18M -10,37M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 512,43M 314,93M 155,42M 31,60M
Total Liabilities 27,78M 9,51M 181,06M 12,10M
Shareholders' Equity 484,65M 305,43M -25,63M 19,51M
Total Debt 11,48M 1,48M 2,15M 10,44M
Cash & Equivalents 52,65M 56,81M 70,17M 31,16M
Current Assets 498,56M 309,80M 150,87M 31,27M
Current Liabilities 19,05M 8,77M 8,80M 1,66M